Atara Biotherapeutics
ATRA
85 hedge funds and large institutions have $509M invested in Atara Biotherapeutics in 2015 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 19 reducing their positions, and 23 closing their positions.
74% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 19
7% less funds holding
Funds holding: 91 → 85 (-6)
17% less capital invested
Capital invested by funds: $614M → $509M (-$106M)
26% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 23
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
65% less call options, than puts
Call options by funds: $472K | Put options by funds: $1.35M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$14.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.6M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$10.5M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$8.8M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$7.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$26.5M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$25.3M |
| 3 |
BAMCO Inc
New York
|
-$24.1M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.2M |
| 5 |
JP Morgan Chase
New York
|
-$3.49M |
ATRA Hedge Fund Activity: Q4 2015 in Review
85 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q4 2015, worth a combined $509M — down 17% from $614M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ATRA and 17 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 33 added.
The largest buyer was Redmile Group, adding an estimated $14.7M. The largest seller was Jennison Associates, exiting entirely with an estimated $26.5M sold.
- 85 institutional investors held Atara Biotherapeutics (ATRA) as of Q4 2015, down from 91 in Q3 2015.
- Funds reported $509M of Atara Biotherapeutics stock for Q4 2015, down 17% quarter-over-quarter.
- 17 funds opened new Atara Biotherapeutics positions in Q4 2015 and 23 closed out, a net change of -6 holders.
- The largest Atara Biotherapeutics buyer in Q4 2015 was Redmile Group, an estimated $14.7M added.
- The largest Atara Biotherapeutics seller in Q4 2015 was Jennison Associates, an estimated $26.5M sold.
Based on aggregated 13F filings for Q4 2015.